Repare Therapeutics Inc. Announces Chief Scientific Officer Departure and Separation Agreement

Repare Therapeutics Inc. has announced the resignation of its Chief Scientific Officer, Michael Zinda, Ph.D., effective December 31, 2025. Dr. Zinda has entered into a separation agreement that includes a base salary payment, a retention payment, his target annual bonus, continued health insurance coverage under COBRA for up to 12 months, accelerated vesting of equity awards, and an extended post-termination exercise period for stock options. The agreement also outlines potential "CIC Separation Benefits" if a change of control event occurs, which would include a higher lump sum payment, the retention and bonus payments (if not already paid), COBRA premium benefits, accelerated vesting of equity, and an extended post-termination option exercise period. The company is also proceeding with a proposed acquisition by XenoTherapeutics, Inc. and Xeno Acquisition Corp., with a shareholder meeting scheduled for January 16, 2026, to approve the transaction. Further details regarding the transaction and the separation agreement are available in the company's filings with the SEC.